Seagen to Highlight Data from Novel Targeted Therapies at AACR
April 09 2021 - 8:00AM
Business Wire
-Data Showcase Depth of Oncology Pipeline Using
Seagen’s Innovative Technologies-
Seagen Inc. (Nasdaq: SGEN) today announced that preclinical data
from its pipeline of novel targeted oncology drugs will be
presented at the American Association for Cancer Research (AACR)
Annual Meeting being held April 10-15, 2021. The oral and poster
presentations will highlight several early-stage programs utilizing
Seagen’s leading antibody-drug conjugate (ADC) technology as well
as its proprietary sugar-engineered antibody (SEA) technology.
“Our research being presented at AACR describes intriguing
preclinical data for three novel pipeline programs that are in
ongoing clinical trials. This includes SEA-TGT, an anti-TIGIT
antibody using our SEA technology, and two vedotin-based ADCs,
SGN-B6A and SGN-STNV. We believe these three programs represent
potential best-in-class or first-in-class targeted therapies for
cancer,” said Roger Dansey, M.D., Chief Medical Officer at Seagen.
“Among the findings, we will show the enhanced therapeutic effect
in combining SEA-TGT with a checkpoint inhibitor or a vedotin-based
ADC across different tumor models. In addition, we will report for
the first time our preclinical data with SGN-STNV, a novel ADC
targeting a carbohydrate antigen that may have broad applicability
across solid tumors.”
Highlights of Seagen Programs Presented at AACR
SEA-TGT
Preclinical data will be presented for SEA-TGT, a novel
investigational nonfucosylated human IgG1 TIGIT antibody, which
utilizes Seagen’s proprietary SEA technology that enhances
functionality by targeting key immune activating Fc receptors.
TIGIT is an inhibitory immune checkpoint that has emerged as a
clinically relevant immuno-oncology target. The monotherapy and
combinatorial activity of SEA-TGT was assessed and compared to
TIGIT monoclonal antibodies (mAbs) with inert, standard, or
effector function modified backbones in vivo and in vitro. Key
preclinical findings were as follows:
- the SEA-TGT backbone was distinct as it increased binding to
activating FcγRIIIa with minimal binding to inhibitory
FcγRIIb;
- the empowered backbone had superior therapeutic properties
including enhanced depletion of TIGIT-positive regulatory T-cells
and activation of antigen-presenting cells both of which are
important in promoting antitumor activity;
- SEA-TGT demonstrated enhanced antitumor activity both as a
single agent and in combination with anti-PD1 therapy; and,
- SEA-TGT produced an enhanced therapeutic effect when combined
with an immunogenic tumor cell death-inducing vedotin ADC.
A phase 1 trial evaluating SEA-TGT alone and in combination with
anti-PD-1 therapy in patients with advanced solid tumors and select
lymphomas is ongoing.
SGN-B6A
Preclinical data will also be presented on SGN-B6A, an
investigational ADC targeting integrin beta-6, which is
overexpressed in numerous solid tumors and has been demonstrated to
be a negative prognostic indicator across a diverse range of
cancers, including non-small cell lung cancer (NSCLC). Data
demonstrate SGN-B6A is active when dosed weekly in patient-derived
xenograft models of NSCLC, representing both squamous and
adenocarcinoma histology. A phase 1 trial evaluating monotherapy
SGN-B6A in advanced solid tumors is ongoing.
SGN-STNV
SGN-STVN is an investigational ADC with a unique mechanism for
targeting a carbohydrate antigen called Sialyl-Thomsen nouveau
(STn), which is highly expressed on a variety of solid tumors
including non-small cell lung, ovarian and gastric cancers. The
preclinical data demonstrate SGN-STNV is highly specific for STn
independent of protein identity, which could allow for the
targeting of a range of tumor types that express different
glycoproteins. In xenograft studies across key tumor types, the
specificity and ability to target STn on multiple tumor-associated
proteins led to durable tumor regressions. SGN-STNV was
well-tolerated in in vivo studies and is being evaluated in an
ongoing phase 1 study.
Additional Details of Seagen Presentations at AACR Annual
Meeting 2021
All poster presentations will be available via on-demand view
starting on April 10 at 8:30 a.m. Eastern Time. Oral symposium
presentations will be available at the beginning of the session
where the study is presented.
Abstract Title
Abstract #
Date
Presenter
Oral
Targeting Sialyl-Thomsen nouveau (STn)
antigen with the SGN-STNV antibody-drug conjugate is effective in
preclinical studies
#50
April 10 in session at 4:00 –
6:00 p.m. ET
A. Schwartz
E-Poster
SEA-TGT is an empowered anti-TIGIT
antibody that displays superior combinatorial activity with several
therapeutic agents
#1583
April 10
A. Smith
Activity of SGN-B6A in patient-derived
xenograft models of non-small cell lung cancer
#914
April 10
R. Lyon
Pharmacokinetics of tucatinib in healthy
and hepatically-impaired volunteers
#1371
April 10
A. Topletz-Erickson
About Seagen
Seagen is a global biotechnology company that discovers,
develops and commercializes transformative cancer medicines to make
a meaningful difference in people’s lives. Seagen is headquartered
in the Seattle, Washington area, and has locations in California,
Canada, Switzerland and the European Union. For more information on
the company’s marketed products and robust pipeline, visit
www.seagen.com and follow @SeagenGlobal on Twitter.
Forward-Looking Statements
Certain of the statements made
in this press release are forward-looking, such as those, among
others, relating to the potential of the Company’s SEA-TGT, SGN-B6A
and SGN-STNV product candidates, the enhanced therapeutic
effect in combining SEA-TGT with a checkpoint inhibitor or a
vedotin-based ADC and the
potential of the Company’s pipeline. Actual results or developments
may differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a
difference include without limitation the difficulty and
uncertainty of pharmaceutical product development, the risk of
adverse events or safety signals, the inability to show sufficient
efficacy in clinical trials and the possibility of adverse
regulatory actions. More information about the risks and
uncertainties faced by Seagen is contained under the caption “Risk
Factors” included in the Company’s Annual Report on Form 10-K for
the year ended December 31, 2020 filed with the Securities and
Exchange Commission. Seagen disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210409005061/en/
Peggy Pinkston (425) 527-4160 ppinkston@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024